Related Experiment Video

Updated: May 17, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

[Management of chronic hepatitis C in 2012 in Belgium]

C Moreno1, P Deltenre

  • 1Clinique d'Hépatologie, Service de Gastroentérologie, Hépatopancréatologie et Oncologie digestive, Hôpital Erasme, Bruxelles. christophe.moreno@erasme.ulb.ac.be

Revue Medicale De Bruxelles
|October 25, 2012
PubMed

Insights

Chronic hepatitis C virus infection requires careful management and monitoring of liver fibrosis. Current treatments offer improved viral eradication but present challenges, necessitating expert care and ongoing research for future therapies.

Area of Science:

  • Hepatology and Virology
  • Public Health
  • Pharmacology

Context:

  • Chronic hepatitis C virus (HCV) infection is a significant global health concern, with a substantial risk of developing cirrhosis.
  • Accurate staging of liver fibrosis is crucial for managing HCV-infected patients.
  • Noninvasive methods, including serum markers and transient elastography (FibroScan), aid in fibrosis assessment.

Purpose:

  • To review the current landscape of chronic hepatitis C management, focusing on treatment goals and therapeutic advancements.
  • To highlight the efficacy and challenges associated with current standard-of-care therapies.
  • To discuss the evolving treatment paradigms and future directions in HCV eradication.

Summary:

  • The primary therapeutic goal is achieving a sustained virological response (SVR), indicating viral eradication.
  • Standard treatment for non-genotype-1 HCV involves pegylated interferon and ribavirin.
  • Genotype-1 HCV, the most common form, is treated with triple therapy (pegylated interferon, ribavirin, and a first-generation protease inhibitor), improving eradication rates but introducing complexities.
  • These complexities include adherence, side effects, drug interactions, and resistance, demanding specialized clinical management.

Impact:

  • Current triple therapies significantly increase the likelihood of viral eradication for hepatitis C.
  • Expert management is essential to navigate the challenges associated with advanced HCV treatments.
  • Emerging antiviral agents in clinical development promise higher eradication rates for most infected individuals in the near future.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations: